Triglyceride as a Factor in Residual CVD Risk

Friday, May 13, 2022

11:00 AM – 12:00 PM

Location: Breakout Room 2- Sapphire OP (Level 4)

Speaker(s)

Eliot A. Brinton, MD, FACE, FAHA, FNLA
President
Utah Lipid Center
Salt Lake City, Utah, United States

Disclosure: 89bio (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- January 1, 2021); Amarin (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing), Research Support (Status: Ongoing); Amgen (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing), Honorarium (Status: Ongoing); Amryt (Self) : Honorarium (Status: Ongoing); Dalcor (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Esperion (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- August 1, 2021), Honorarium (Status: Terminated --- August 1, 2021); Genzyme () : Speaker's Bureau; Kowa (Self) : Grant/Research Support (Status: Ongoing); Merck () : Consultant, Speaker's Bureau; Novartis (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing); Pfizer (Self) : Consulting Fees (e.g., advisory boards) (Status: Ongoing)

PDF Slides

Moderator(s)

Betul Hatipoglu, MD
Professor of Medicine
Case Western Reserve University/ University Hospitals
Beachwood, Ohio, United States

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Learning Objectives:

Discuss the prevalence and importance of mild to moderate elevations of fasting triglycerides (TG) as a risk factor for atherosclerotic cardiovascular disease (ASCVD)
Discuss the biology of eicosapentaenoic acid (EPA) vs docosahexaenoic acid (DHA) as it applies to clinical practice
Implement appropriate criteria for use of prescription icosapent ethyl (IPE) in ASCVD prevention (in place of DHA and fibrates)

Participants should be aware of the following financial/non-financial relationships:

Eliot A. Brinton, MD, FACE, FAHA, FNLA: 89bio (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Amarin (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Honorarium, Research Support; Amgen (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Honorarium; Amryt (Individual(s) Involved: Self): Honorarium; Dalcor (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Esperion (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards), Honorarium; Genzyme: Speaker's Bureau; Kowa (Individual(s) Involved: Self): Grant/Research Support; Merck: Consultant, Speaker's Bureau; Novartis (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Pfizer (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards)

Betul Hatipoglu, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.